These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 7516262)
1. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Ohori M; Wheeler TM; Scardino PT Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262 [TBL] [Abstract][Full Text] [Related]
2. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification]. Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634 [TBL] [Abstract][Full Text] [Related]
3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL; J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734 [TBL] [Abstract][Full Text] [Related]
4. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Epstein JI; Walsh PC; Carmichael M; Brendler CB JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging. Augustin H; Graefen M; Palisaar J; Blonski J; Erbersdobler A; Daghofer F; Huland H; Hammerer PG J Clin Oncol; 2003 Aug; 21(15):2860-8. PubMed ID: 12885802 [TBL] [Abstract][Full Text] [Related]
6. Are prostate carcinoma clinical stages T1c and T2 similar? Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293 [TBL] [Abstract][Full Text] [Related]
7. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Zagars GK; Geara FB; Pollack A; von Eschenbach AC Cancer; 1994 Apr; 73(7):1904-12. PubMed ID: 7511040 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Cookson MS; Fleshner NE; Soloway SM; Fair WR Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696 [TBL] [Abstract][Full Text] [Related]
10. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml. Geary ES; Stamey TA J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306 [TBL] [Abstract][Full Text] [Related]
11. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? Soh S; Kattan MW; Berkman S; Wheeler TM; Scardino PT J Urol; 1997 Jun; 157(6):2212-8. PubMed ID: 9146618 [TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388 [TBL] [Abstract][Full Text] [Related]
13. Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy. Furuya Y; Ohta S; Sato N; Kotake T; Masai M Int Urol Nephrol; 2002; 33(1):73-6. PubMed ID: 12090344 [TBL] [Abstract][Full Text] [Related]
16. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Kawakami S; Kihara K; Fujii Y; Masuda H; Kobayashi T; Kageyama Y Int J Urol; 2004 Aug; 11(8):613-8. PubMed ID: 15285751 [TBL] [Abstract][Full Text] [Related]
17. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. Hoedemaeker RF; Rietbergen JB; Kranse R; van der Kwast TH; Schröder FH World J Urol; 1997; 15(6):339-45. PubMed ID: 9436283 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Mettlin C; Murphy GP; Lee F; Littrup PJ; Chesley A; Babaian R; Badalament R; Kane RA; Mostofi FK Cancer; 1993 Sep; 72(5):1701-8. PubMed ID: 7688658 [TBL] [Abstract][Full Text] [Related]
19. Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. Tiguert R; Gheiler EL; Grignon DJ; Littrup PJ; Sakr W; Pontes JE; Wood DP J Urol; 2000 May; 163(5):1486-90. PubMed ID: 10751863 [TBL] [Abstract][Full Text] [Related]
20. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? Ohori M; Kattan MW; Utsunomiya T; Suyama K; Scardino PT; Wheeler TM J Urol; 2003 Mar; 169(3):964-8. PubMed ID: 12576823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]